Vadimezan (Synonyms: DMXAA; ASA-404)

Name: Vadimezan
Brand: MedChemExpress
SKU: HY-10964
Rating: 5.0 (48 reviews)

Cat. No.: HY-10964 Purity: 99.80%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.

For research use only. We do not sell to patients.

Vadimezan Chemical Structure

CAS No. : 117570-53-3

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 106	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 106	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 70	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
20 mg	USD 180	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 370	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 590	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 48 publication(s) in Google Scholar

44 Publications Citing Use of MCE Vadimezan

: Vadimezan purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2023 Apr 30;20(1):101. [Abstract]; Vadimezan (DMXAA; 20 mg/kg; i.p.; daily; two days) significantly upregulates the morphine-induced decreased expression of STING in the spinal dorsal horn of mice.

: Vadimezan purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2023 Apr 30;20(1):101. [Abstract]; Vadimezan (DMXAA; 20 mg/kg; i.p.; one dose) inhibits morphine-reduced spinal STING fluorescence intensity in mice.

: Vadimezan purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Feb 28;42(3):112145. [Abstract]; Vadimezan (DMXAA; 50 µM; 4, 6 h) significantly increases the level of IRG1 in RAW264.7 macrophages.

: Vadimezan purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2018 May;154(6):1822-1835.e2. [Abstract]; Expression of IRF3, p-IRF3, p65 and p-p65 in whole pancreatic extract of acute pancreatitis (AP) mice shown by western blot.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

STING^[1], type I IFNs^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1039/C3MD00372H
A549	IC₅₀	207.6 μM Compound: 1, DMXAA, Vadimezan	Indirect cytotoxicity against human A549 cells co-cultured with mouse RAW264.7 cells after 24 hrs by MTT assay Indirect cytotoxicity against human A549 cells co-cultured with mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 24518295]
A549	IC₅₀	345 μM Compound: 1, DMXAA, Vadimezan	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 24518295]
A549	IC₅₀	91 μM Compound: 1, DMXAA, Vadimezan	Indirect cytotoxicity against human A549 cells co-cultured with human PBMC after 24 hrs by MTT assay Indirect cytotoxicity against human A549 cells co-cultured with human PBMC after 24 hrs by MTT assay	[PMID: 24518295]
Bel-7402	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	10.1039/C3MD00372H
BeWo	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human Bewo cells after 48 hrs by MTT assay Cytotoxicity against human Bewo cells after 48 hrs by MTT assay	10.1039/C3MD00372H
BGC-823	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	10.1039/C3MD00372H
BJ	CC₅₀	48.9 μM Compound: 1, DMXAA, Vadimezan	Cytotoxicity against human BJ cells after 24 hrs by MTT assay Cytotoxicity against human BJ cells after 24 hrs by MTT assay	[PMID: 24518295]
COLO 320	IC₅₀	39.5 μM Compound: DMXAA	Antiproliferative activity against human COLO320 cells after 48 hrs by CCK8 assay Antiproliferative activity against human COLO320 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
H69AR	EC₅₀	> 100 μM Compound: 4; DMXAA	Agonist activity at STING in human THP1 Dual cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay Agonist activity at STING in human THP1 Dual cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay	[PMID: 35108011]
H69AR	EC₅₀	> 100 μM Compound: 4; DMXAA	Agonist activity at STING in human THP1-Dual cells assessed as NF-kappaB reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay Agonist activity at STING in human THP1-Dual cells assessed as NF-kappaB reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay	[PMID: 35108011]
HeLa	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	10.1039/C3MD00372H
HepG2	IC₅₀	100.2 μM Compound: DMXAA	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
HepG2	IC₅₀	100.2 μM Compound: DMXAA	Growth inhibition of human HepG2 cells after 24 hrs by MTT assay Growth inhibition of human HepG2 cells after 24 hrs by MTT assay	[PMID: 29609121]
HepG2	IC₅₀	100.2 μM Compound: DMXAA; D	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 29129511]
HepG2	IC₅₀	21.25 μM Compound: DMXAA; D	Antiproliferative activity against human HepG2 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay	[PMID: 29129511]
HL-60	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	10.1039/C3MD00372H
HT-29	IC₅₀	269.5 μM Compound: 1, DMXAA, Vadimezan	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 24518295]
HUVEC	IC₅₀	> 20 μM Compound: 6, Vadimezan	Cytotoxicity against HUVEC assessed as mitochondrial metabolism after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as mitochondrial metabolism after 48 hrs by MTT assay	10.1039/C3MD00372H
Ishikawa	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human Ishikawa cells after 48 hrs by MTT assay Cytotoxicity against human Ishikawa cells after 48 hrs by MTT assay	10.1039/C3MD00372H
K562	IC₅₀	19.14 μM Compound: DMXAA; D	Antiproliferative activity against human K562 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay Antiproliferative activity against human K562 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay	[PMID: 29129511]
K562	IC₅₀	57.4 μM Compound: DMXAA	Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
K562	IC₅₀	57.44 μM Compound: DMXAA; D	Antiproliferative activity against human K562 cells after 24 hrs by MTT assay Antiproliferative activity against human K562 cells after 24 hrs by MTT assay	[PMID: 29129511]
L02	IC₅₀	< 100 μM Compound: DMXAA	Cytotoxicity against human HL-7702 cells after 48 hrs by CCK8 assay Cytotoxicity against human HL-7702 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
L02	IC₅₀	< 100 μM Compound: DMXAA	Cytotoxicity against human HL-7702 cells after 48 hrs in presence of DMXAA by CCK8 assay Cytotoxicity against human HL-7702 cells after 48 hrs in presence of DMXAA by CCK8 assay	[PMID: 28376372]
L02	IC₅₀	101.3 μM Compound: DMXAA; D	Antiproliferative activity against human HL-7702 cells after 24 hrs by MTT assay Antiproliferative activity against human HL-7702 cells after 24 hrs by MTT assay	[PMID: 29129511]
MCF7	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	10.1039/C3MD00372H
MCF7	IC₅₀	11.89 μM Compound: DMXAA; D	Antiproliferative activity against human MCF7 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay	[PMID: 29129511]
MCF7	IC₅₀	54.4 μM Compound: DMXAA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
MCF7	IC₅₀	54.4 μM Compound: DMXAA	Growth inhibition of human MCF7 cells after 24 hrs by MTT assay Growth inhibition of human MCF7 cells after 24 hrs by MTT assay	[PMID: 29609121]
MCF7	IC₅₀	54.41 μM Compound: DMXAA; D	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 29129511]
MDA-MB-231	IC₅₀	12.12 μM Compound: DMXAA; D	Antiproliferative activity against human MDA-MB-231 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay	[PMID: 29129511]
MDA-MB-231	IC₅₀	48.4 μM Compound: DMXAA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
MDA-MB-231	IC₅₀	48.42 μM Compound: DMXAA	Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29609121]
MDA-MB-231	IC₅₀	48.44 μM Compound: DMXAA; D	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29129511]
NIH3T3	IC₅₀	< 100 μM Compound: DMXAA	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by CCK8 assay	[PMID: 28376372]
NIH3T3	IC₅₀	< 100 μM Compound: DMXAA	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs in presence of DMXAA by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs in presence of DMXAA by CCK8 assay	[PMID: 28376372]
NIH3T3	IC₅₀	67.8 μM Compound: DMXAA; D	Antiproliferative activity against mouse NIH/3T3 cells after 24 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 29129511]
SiHa	IC₅₀	> 100 μM Compound: 6, Vadimezan	Cytotoxicity against human SiHa cells after 48 hrs by MTT assay Cytotoxicity against human SiHa cells after 48 hrs by MTT assay	10.1039/C3MD00372H

In Vitro

Vadimezan (DMXAA), the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan (DMXAA) has no detrimental effect on 344SQ-ELuc cell viability. It is found that Vadimezan-mediated up regulation of the NF-κB pathway as shown by increased p65 phosphorylation in M2 macrophages^[1]. Results demonstrate that Vadimezan (DMXAA)-treated cells are protected from VSV-induced cytotoxicity at all MOIs in contrast to medium-pretreated macrophages. Vadimezan (DMXAA) effectively inhibits growth of both strains of influenza, demonstrating the potential of Vadimezan for treatment of drug-resistant strains of human influenza^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

344SQ-ELuc NSCLC subcutaneous tumors respond dramatically to Vadimezan (DMXAA), with a marked decrease in bioluminescence (BLI) signals post-drug injection. Vadimezan (DMXAA) treatment of 344SQ-ELuc metastases yields no decrease in photon emission rates, with the tumors remaining histologically similar to controls after this treatment. As with the large subcutaneous tumors, Vadimezan (DMXAA) administration to mice with small subcutaneous tumors still leads to ~2-log decreases in photon emission at both 6 and 24 hours^[1]. In vivo, Vadimezan (DMXAA) is a more potent inducer of IFN-β mRNA and a relatively poor inducer of TNF-α mRNA. Vadimezan (DMXAA) administration leads to significantly less weight loss in influenza-infected mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

282.29

Formula

C₁₇H₁₄O₄

CAS No.

117570-53-3

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 7.14 mg/mL (25.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

7.5% sodium bicarbonate : 6.67 mg/mL (23.63 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5425 mL	17.7123 mL	35.4246 mL
5 mM	0.7085 mL	3.5425 mL	7.0849 mL
10 mM	0.3542 mL	1.7712 mL	3.5425 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.71 mg/mL (2.52 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (17.71 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.80%

Select Batch:

Data Sheet (281 KB) SDS (537 KB)

COA (249 KB) LCMS (267 KB)

Handling Instructions (2659 KB)

References

[1]. Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9(6):e99988. [Content Brief]

[2]. Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7. [Content Brief]

Kinase Assay ^[1]	M2-polarized macrophages are treated with 20 µg/mL Vadimezan (ASA-404) or DMSO vehicle for 30 min. Cells are then lysed and protein denatured in SDS buffer and samples sent for RPPA analysis. Differential abundance of various proteins and/or their phosphorylation status in response to Vadimezan (ASA-404) is assessed^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[2]	RAW 264.7 macrophages are cultured and plated at 1×10⁵ cells/well in a 96-well plate. After overnight incubation at 37°C, cells are treated with medium containing vehicle or Vadimezan (DMXAA) (100 μg/mL). After 6 h, the culture medium is replaced with serum-free DMEM containing VSV at the indicated MOI for 1 h. Cells are then maintained in complete DMEM with 10% FBS. Twenty-four hours later, cells are washed with PBS, fixed with 10% buffered formalin, and rinsed thoroughly with distilled water. Adherent cells are stained with crystal violet^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Male 129/Sv mice (6 to 12 week old) are used in this study. To generate subcutaneous tumors, 5×10⁵ 344SQ-ELuc cells in 100 µL PBS are injected in both posterior flanks of mice. Tumor growth is monitored every 2 to 4 days via BLI. Once tumors are established (day 10 for systemic metastases; day 7 or day 14 for subcutaneous tumors), mice are given 25 mg/kg of Vadimezan (DMXAA), or DMSO vehicle by i.p. injection. BLI is carried out at 6 and 24 hours ^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9(6):e99988. [Content Brief] [2]. Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

7.5% sodium bicarbonate / DMSO	1 mM	3.5425 mL	17.7123 mL	35.4246 mL	88.5614 mL
	5 mM	0.7085 mL	3.5425 mL	7.0849 mL	17.7123 mL
	10 mM	0.3542 mL	1.7712 mL	3.5425 mL	8.8561 mL
	15 mM	0.2362 mL	1.1808 mL	2.3616 mL	5.9041 mL
	20 mM	0.1771 mL	0.8856 mL	1.7712 mL	4.4281 mL
DMSO	25 mM	0.1417 mL	0.7085 mL	1.4170 mL	3.5425 mL

Vadimezan Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Vadimezan (Synonyms: DMXAA; ASA-404)

Customer Review

44 Publications Citing Use of MCE Vadimezan

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vadimezan Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Vadimezan (Synonyms: DMXAA; ASA-404)

Customer Review

Vadimezan Related Antibodies

44 Publications Citing Use of MCE Vadimezan

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Vadimezan Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vadimezan Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report